Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
35.98
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.55 - 41.63
Open     -
Vol / Avg. 0.00/928,300.00
Mkt cap 1.57B
P/E     -
Div/yield     -
EPS -1.70
Shares 43.59M
Beta 0.74
Inst. own 78%
Jul 27, 2015
Q2 2015 Cempra Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 21, 2015
Cempra Inc Annual Shareholders Meeting
Apr 30, 2015
Q1 2015 Cempra Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Cempra Inc Earnings Release
Mar 18, 2015
Cempra Inc at Jefferies Antibiotic Summit Investor Conference
Mar 12, 2015
Cempra Inc at Barclays Healthcare Conference
Mar 2, 2015
Cempra Inc at Cowen Health Care Conference
Feb 25, 2015
Q4 2014 Cempra Inc Earnings Call - Webcast
Feb 25, 2015
Q4 2014 Cempra Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -124.73% -405.16%
Operating margin -120.34% -390.38%
EBITD margin - -389.88%
Return on average assets -42.13% -60.35%
Return on average equity -56.92% -94.12%
Employees 55 -
CDP Score - -

Address

6320 Quadrangle Dr Ste 360
CHAPEL HILL, NC 27517-7890
United States - Map
+1-919-5762306 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product is solithromycin (CEM-101) is for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin is active against many key CABP pathogens as well as against pneumococcal strains resistant to other macrolides. The product is in Phase III clinical trials. The Company’s Taksta is an antibiotic used for the long term oral treatment of prosthetic joint infections (PJI), caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus (MRSA). The product has completed the Phase II clinical trials.

Officers and directors

Garheng Kong M.D., Ph.D. Independent Chairman of the Board
Age: 39
Bio & Compensation  - Reuters
Prabhavathi B. Fernandes Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Mark W. Hahn Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
David S. Moore Executive Vice President, Chief Commercial Officer
Age: 41
Bio & Compensation  - Reuters
David W. Oldach Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
David N. Gill Independent Director
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 57
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters